Nalaganje...
Comparison of the pharmacodynamic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trial
Further to the patent expiry of Neupogen® (Amgen filgrastim), Hospira has developed a biosimilar filgrastim (Nivestim™) that may offer a clinically effective alternative for multiple hematologic and oncologic indications. Here results are reported from a phase I trial, primarily designed to compare...
Shranjeno v:
| Main Authors: | , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Springer-Verlag
2010
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2924967/ https://ncbi.nlm.nih.gov/pubmed/20567823 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00277-010-0973-6 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|